Literature DB >> 23603342

Guanine nucleotide binding protein β 1: a novel transduction protein with a possible role in human breast cancer.

Umar Wazir1, Wen G Jiang, Anup K Sharma, Kefah Mokbel.   

Abstract

UNLABELLED: To our knowledge, this is the first study to examine the relationship between guanine nucleotide binding protein β-1 (GNB1) mRNA expression and clinicopathological parameters. Furthermore, the correlations between GNB1, Rictor and the mammalian target of rapamycin (mTOR) were also investigated.
MATERIALS AND METHODS: Breast cancer tissues (n=136) and normal tissues (n=31) underwent reverse transcription and quantitative polymerase chain reaction. Transcript levels were correlated with clinicopathological data.
RESULTS: Higher mRNA transcript levels of GNB1 were found in the breast cancer specimens in paired samples (p=0.0029). The mRNA expression of GNB1 increased with TNM stage (TNM1 vs. TNM2/3/4, p=0.036), tumour grade (grade 2 vs. 3, p=0.006), in ductal tumours (p=0.0081), and was associated with adverse patient outcomes (mortality vs. disease-free survival: 4.9 vs. 0.01, p=0.027). GNB1 was positively-correlated with mTOR (r=0.525, p<0.000001) and Rictor (r=0.388, p=0.0000606).
CONCLUSION: These observations may suggest that GNB1 plays an important role in the mTOR-related anti-apoptosis pathway and can potentially be targeted in the treatment of human breast cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23603342

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  8 in total

1.  Many si/shRNAs can kill cancer cells by targeting multiple survival genes through an off-target mechanism.

Authors:  William Putzbach; Quan Q Gao; Monal Patel; Stijn van Dongen; Ashley Haluck-Kangas; Aishe A Sarshad; Elizabeth T Bartom; Kwang-Youn A Kim; Denise M Scholtens; Markus Hafner; Jonathan C Zhao; Andrea E Murmann; Marcus E Peter
Journal:  Elife       Date:  2017-10-24       Impact factor: 8.140

2.  Chromosomal Aberrations in Canine Gliomas Define Candidate Genes and Common Pathways in Dogs and Humans.

Authors:  Peter J Dickinson; Dan York; Robert J Higgins; Richard A LeCouteur; Nikhil Joshi; Danika Bannasch
Journal:  J Neuropathol Exp Neurol       Date:  2016-05-31       Impact factor: 3.685

3.  Plasma membrane proteomics of human breast cancer cell lines identifies potential targets for breast cancer diagnosis and treatment.

Authors:  Yvonne S Ziegler; James J Moresco; Patricia G Tu; John R Yates; Ann M Nardulli
Journal:  PLoS One       Date:  2014-07-16       Impact factor: 3.240

4.  Systems Perturbation Analysis of a Large-Scale Signal Transduction Model Reveals Potentially Influential Candidates for Cancer Therapeutics.

Authors:  Bhanwar Lal Puniya; Laura Allen; Colleen Hochfelder; Mahbubul Majumder; Tomáš Helikar
Journal:  Front Bioeng Biotechnol       Date:  2016-02-11

5.  Pooled screening for antiproliferative inhibitors of protein-protein interactions.

Authors:  Satra Nim; Jouhyun Jeon; Carles Corbi-Verge; Moon-Hyeong Seo; Ylva Ivarsson; Jason Moffat; Nadya Tarasova; Philip M Kim
Journal:  Nat Chem Biol       Date:  2016-02-22       Impact factor: 15.040

6.  Predicting MicroRNA Target Genes and Identifying Hub Genes in IIA Stage Colon Cancer Patients Using Bioinformatics Analysis.

Authors:  Zhiyong Dong; Wei Lin; Stacy A Kujawa; Shike Wu; Cunchuan Wang
Journal:  Biomed Res Int       Date:  2019-02-07       Impact factor: 3.411

7.  Shikonin induces cell autophagy via modulating the microRNA -545-3p/guanine nucleotide binding protein beta polypeptide 1 axis, thereby disrupting cellular carcinogenesis in colon cancer.

Authors:  ZhiWei Hu; XinDong Zhou; DeQiang Zeng; JiaJun Lai
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

8.  Methylation of leukocyte DNA and ovarian cancer: relationships with disease status and outcome.

Authors:  Brooke L Fridley; Sebastian M Armasu; Mine S Cicek; Melissa C Larson; Chen Wang; Stacey J Winham; Kimberly R Kalli; Devin C Koestler; David N Rider; Viji Shridhar; Janet E Olson; Julie M Cunningham; Ellen L Goode
Journal:  BMC Med Genomics       Date:  2014-04-28       Impact factor: 3.063

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.